Praxis Precision Medicines Wins FDA Breakthrough Status for Elsunersen in Rare Epilepsy Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year. Credit: Praxis Precision Medicines Subscribe now Already have an account? Sign in.
